The Effects of Nootropic Drugs on Striatal 5-HT2A-Receptors in Outbred Mice with Different Efficacy of Exploratory Behavior

Resume. The effect of subchronic administration of nootropic drugs of different structures (piracetam 200 mg/kg/day, pantocalcin 200 mg/kg/day, semax 0.6 mg/ kg/day, nooglutil 50 mg/kg/day) to mice of the outbred line 1CR on spontaneous research activity in a closed cross-maze and on the binding characteristics of 5-HT_2A-receptors in striatal membranes. In experiments using [³H] (+)Ketanserin, it has been established that the mice brains exhibiting a low efficacy of exploratory behavior (LEEB) in the closed cross-maze test has a lower density of 5-HT_2A receptors (B_max = 519 ± 13 fmol/ mg , p = 0.02) in comparison with the subpopulation with high efficacy of exploratory behavior (HEEB) (639 ± 48 fmol / mg). After 5-fold administration of nootropics, only in groups with LEEB there was a significant increase in the Bmax value under the action of all investigated nootropics: piracetam (643 ± 42 fmol/mg); pantocalcine (662 ± 29 fmol/mg); semax (742 ± 29 fmol/mg) and nooglutil (1145 fmol/mg) at p = 0.01. By the Kd value, the subpopulations did not initially differ and did not undergo significant changes under the action of the drugs. The presence of serotonin-positive effects of all drugs studied in animals with initially reduced receptor density is consistent with the hypothesis of the selective, modulating nature of the nootropics action.

ноотропы, 5-НТ_2А-рецепторы, [G-³Н](+)Кетансерин, пирацетам, нооглютил, семакс, пантокальцин, стриатум, крестообразный лабиринт, исследовательское поведение, nootropics, 5-HT_2A-receptors, [G-³H] (+) Ketanserin, piracetam, nooglutil, semax, pantocalcine, striatum, closed cross-maze, exploratory behavior

1. Archer T. Serotonin and fear retention in the rat. J. Сотр Physiol Psychol. 1982;96:491- 516. DOI: 10.1037/h0077897

2. Aghajanian GK, Andrade R. Electrophysiology of 5-HT receptors. In: Baumgarten HG, Gothert M., eds. Serotonergic neurons and 5-HT receptors in the CNS. Berlin: Хргіп§ег-УегІа§; 1997. p. 499- 535. DOI: 10.1007/978-3-642-60921-3_19

3. Harvey JA. Role of the Serotonin 5-HT 2A Receptor in Learning. Learning & Memory. 2003;10(5):355- 362. DOI: 10.1101/lm.60803

4. Aznar S., El-Sayed Hervig M. The 5-HT2A serotonin receptor in executive function: Implications for neuropsychiatric and neurodegenerative diseases. Aeuroscience & Biobehavioral Reviews. 2016;64:63- 82. DOI: 10.1016/j.neubiorev.2016.02.008

5. Prinssen EP, Kleven MS, Коек W. Effects of dopamine antagonists in a two way active avoidance procedure in rats: Interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology. 1996;128:191- 197. DOI: 10.1007/s002130050124

6. Luciana M., Collins PF, Depue RA. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cerebral Cortex. 1998;8:218- 226. DOI: 10.1093/cercor/8.3.218

7. Zhang C., Marek GJ. AMPA receptor involvement in 5-hydroxytryptamine 2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes. Prog. Aeuropsychopharmacol. Biol. Psychiatry. 2008;32(1):62- 71. DOI: 10.1016/j.pnpbp.2007.07.009.

8. Roth B. Irving Page Lecture: 5-HT 2A serotonin receptor biology: Interacting proteins, kinases and paradoxical regulation. Aeuropharmacology. 2011;61:348- 354. DOI: 10.1016/j.neuropharm.2011.01.012

9. Meneses A. Neurotransmitters and Memory: Cholinergic, Glutamatergic, GABAergic, Dopaminergic, Serotonergic, Signaling, and Memory. Identification of Aeural Markers Accompanying Memory. 2014;5-45. DOI: 10.1016/B978-0-12-408139-0.00002-X

10. Салимов Р.М. Оценка упорядоченности пути в процессе исследовательского поведения у мышей // Журнал высшей нервной деятельности им. И.П. Павлова. - 1988. - Т.38. - №3. - С.569- 571.

11. Ковалев Г.И. Фармакодинамика ноотропных средств. Экспериментальная и клиническая фармакология. - 2018. - Т.81. - №S. - С. 114.

12. Salimov RM, Kovalev GI. Effects of N-cholinergic drugs on behavior in the explorative cross-maze in mice: comparison with cognitive enhancers. Eur. Aeuropsychopharmacology. 2005;15(2):230- 234. DOI: 10.1016/s0924-977x(05)80455-9

13. Ковалев Г.И., Фирстова Ю.Ю., Салимов Р.М. Влияние пирацетама и ацефена на NMDA и никотиновые рецепторы мозга мы шей с различной эффективностью исследовательского поведения в крестообразном лабиринте // Экспериментальная и клиническая фармакология. - 2008. - Т.71. - №1 - С.12-17. DOI: https://doi.org/10.30906/0869-2092-2008-71-1-12-17

14. Ковалёв Г.И., Фирстова Ю.Ю., Салимов Р.М., и др. Механизмы избирательного действия Семакса при когнитивном дефиците у мышей // Психиатрия. - 2010. - Т3. - №45. - С.23- 28.

15. Фирстова Ю.Ю., Абаимов Д.А., Капица И.Г., и др. Влияние скополамина и ноотропного препарата фенотропила на рецепторы нейромедиаторов мозга крыс в тесте условного рефлекса пассивного избегания (УРПИ) // Нейрохимия. - 2011. - Т.28. - №2. - С.130-141.

16. Seger CA. The basal ganglia in human learning. The Aeuroscientist. 2006;12(4):285- 290. DOI: 10.1177/1073858405285632

17. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. / Под ред. Миронова А.Н. - М.: Гриф и К.; 2012.

18. Miguelez C., Morera-Herreras T., Torrecilla M., et al. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson’s disease. Frontiers in Aeural Circuits. 2014;8(21):1-9. DOI: 10.3389/fncir.2014.00021

19. Leysen JE, Niemegeers CJ, Van Nueten JM, et al. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 1982;21(2):301-314.

20. Hasselbalch SG, Madsen K., Svarer C., et al. Reduced 5-HT 2A receptor binding in patients with mild cognitive impairment. Aeurobiology of aging. 2008;29:1830- 1838. DOI: 10.1016/j.neurobiolaging.2007.04.011

21. Фирстова Ю.Ю., Долотов О.В., Кондрахин Е.А., и др. Влияние ноотропных препаратов на уровень BDNF в гиппокампе и коре мозга мышей с различной эффективностью исследовательского поведения // Экспериментальная и клиническая фармакология. - 2009. - Т72. - №6. - С.3-6.